1985

Olavi Kajander observes nanoscale particles in vitro, forming a community, as contaminants in mammalian cell cultures. He surmises that they may be alive. Without training, others fail at culturing due to the nanoscopic size and slow growth.

1986

Kajander observes that some of the particles he found earlier appear to have a hard surface.

1987

Kajander discovers the unique calcific particles in human blood.

1988

Kajander takes first electron microscope pictures of nanobacteria and develops polyclonal antibodies to detect them.

1990

Kajander files for patents for nanobacteria, plus culturing and antibody methods.

1991

Kajander develops new monoclonal antibodies to detect nanobacteria.

1992

Kajander is awarded a patent for nanobacteria and nanobacterial detection methods.

1992

Kajander discovers that nanobacteria make mineralized "igloo-like" structures, explaining the hard surfaces observed earlier.

1992

Kajander et al. publish one of the first abstracts on blood nanobacteria, Nanobacterium sanguineum.

1992

Kajander optimizes the culturing process by developing a unique medium that makes nanobacteria grow quickly and produces colonies on solid media.

1993

Kajander and his Finnish company Nanobac OY optimize methods for detecting nanobacteria antigen as a prototype for the commercial methods used today.

1997

Gary Mezo independently develops his NanobacTX, a pharmaceutical compound to reverse heart disease. Mezo then starts NanobacLabs Pharmaceuticals, the precursor to his Nanobac Pharmaceuticals, Inc. the US publicly traded company. Mezo later buys Kajander's Finnish Company Nanobac OY and the patents from the Finnish Government and hires the scientist Olavi Kajander, MD, PhD. 

1997

Kajander et al. announces discovery of potential nanobacteria contamination in antibody products.

1997

Kajander, et al announce discovery that nanobacteria replicate in rabbits, fulfilling another part of Koch’s postulate.

1998

Kajander announces discoveries & applies for a patent which was later allowed by European and American agencies.

1998

Kajander announces discovery of nanobacteria in kidney stones. The story is covered by journals and news services worldwide.

1998

Kajander announces discovery of nanobacteria in periodontal disease plaque and dental pulp stones.

1999 

László Puskás, PhD (University of Szeged) collaborates with Kajander to detect nanobacteria in atherosclerotic plaques and submits his research findings to prominent scientific journals but has difficulty getting his new findings published.

1999

Nanobac Oy, a Finnish start-up company, begins using diagnostic tests for diagnosing nanobacteria in research patients with heart and kidney disease.

1999-2000

Critic's investigation into Kajander's nanobacterial research shows validity of Kajander's research & methods.

2000

Garcia-Cuerpo et al. fulfill & prove Koch's postulates for proving nanobacteria as infectious disease causing agent.

2000

University of Illinois' Hjelle & Miller announce discovery of nanobacteria in Polycystic Kidney Disease (PKD).

2001

Kajander announces detection of live nanobacteria found as contaminants in sterilized viral vaccines as reported by Vaccines Today and New Scientist.

2001

First Worldwide Nanobacteria Symposium held at University of Kuopio, Finland brings Mezo, Kajander & many other nanobacteria researchers together for the first time.

2002

Clinical study reports on Mezo's NanobacTX by cardiologists, begin to show first formal independent results that severe heart disease patients have sustained substantial reductions in heart disease measurements, symptoms and markers after treatment with NanobacTX.

2002

Rasmussen duplicates Laszlo Puskas' research work, finding nanobacteria in atherosclerotic plaque.

2002

Kajander announces discovery of contamination of immune gamma globulin products with nanobacteria.

2002

Nanobac Pharmaceuticals' CEO & Founder, Gary Mezo designs and begins the first IRB-Monitored cardiovascular study on NanobacTX and Tampa cardiologist, Benedict Maniscalco, MD, FACC independently conducts the study.

2003

Kerner et al. announce discovery of nanobacteria entities that replicate in bacteria-like ways in polluted river water.

2003

Cardiology researcher Maniscalco completes Mezo's first clinical trial of NanobacTX and announces preliminary significant reductions in coronary artery calcium scores and other markers of heart disease that shows the first structural and functional reversal of Coronary Artery Heart Disease.

2003

Olavi Kajander, Benedict Maniscalco and Gary Mezo publish their Unified Theory of Atherogenesis & Treatment based on nanobacterial infection, calcification, inflammation & swelling.

2003

Roland Sedivy and Walter B. Battistutti announce discovery of nanobacteria in calcified adenocarcinomas in ovarian cancer.

2004

Madhu Khullar, S. K. Sharma, S. K. Singh, Pratibha Bajwa, Farooq A. Sheikh, Vandana Relan and Meera Sharma announce that they have isolated nanobacteria from human kidney stones.

2004

The Sino-Finland Nanobacteria Co-Operation Center, an international institute devoted to the study of nanobacteria is started by the University of Kuopio in Finland and the Second Affiliated Hospital Central South University, Changsha, China.

2004

Jelic, Malas, Groves et al announce independent discovery of nanobacteria in the heart valve of end-stage diabetes patient.

2004

Mayo Clinic's John Lieske, MD, PhD et al. announce that they have found RNA-synthesizing nanobacteria organisms in cardiovascular disease.

2004

Stephen Epstein, MD, PhD (NIH Director of cardiovascular research & Director of CV Research at Washing Hospital Medical Center) and Jianhui Zhu, PhD present at the American Heart Assn. Annual Meeting their discovery of a correlation between high levels of coronary artery calcification and
the presence of nanobacteria, They also establish Nanobacterial antigen & antibodies are a higher heart disease risk-factor than is homocysteine or cholesterol. Epstein's studies were done using Mezo's nanobacteria rapid test that can serve as a tool for predicting heart disease risk.

2005

NASA's Nanobacteria Research Center announces that nanobacteria grow faster in microgravity which may explain increased kidney stone formation in astronauts during space flights.

2005

Wen, Y., Kajander, et al annouce that they have detected nanobacteria in serum, bile, and gallbladder mucosa of patients with cholecystolithiasis (gallstones).

2005

Cleveland Clinic's Daniel Shoskes publishes his Urobac study in The Journal of Urology showing our Urobac is effective in reversing chronic prostatitis (CP-CPPSIII), chronic pelvic pain syndrome (CPPS) and prostate stones.

2006

2006-

Tsurumoto, Matsumoto, et al publish their detection of nanobacteria in human arthritic synovial joint fluids.

Our nanobacterial research continues at scores of universities & respected research facilities Worldwide.

NANOBIOTECH PHARMA exclusively develops all Intellectual Property relating to Nanobacterial Nanobiotics, therapies and treatments, including but limited to: NanobacTX, Urobac, & Dermabac.